Approaches to chronic lymphocytic leukemia therapy in the era of new agents: The conundrum of many options Journal Article
| Authors: | Jain, N.; Thompson, P.; Ferrajoli, A.; Nabhan, C.; Mato, A. R.; O'Brien, S. |
| Article Title: | Approaches to chronic lymphocytic leukemia therapy in the era of new agents: The conundrum of many options |
| Abstract: | Three small molecule inhibitors have been approved for the treatment of chronic lymphocytic leukemia (CLL) in the last 4 years. Ibrutinib, idelalisib, and venetoclax are oral agents with excellent efficacy and different toxicity profiles. Issues discussed herein include the current role for chemoimmunotherapy in CLL, the use of oral inhibitors in older patients, and the sequencing of these molecules in daily practice. |
| Keywords: | treatment outcome; antineoplastic agent; antineoplastic combined chemotherapy protocols; pathology; chronic lymphatic leukemia; leukemia, lymphocytic, chronic, b-cell; humans; human |
| Journal Title: | American Society of Clinical Oncology Educational Book |
| Volume: | 38 |
| ISSN: | 1548-8756 |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-23 |
| Start Page: | 580 |
| End Page: | 591 |
| Language: | English |
| DOI: | 10.1200/edbk_200691 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 3 December 2018 -- Source: Scopus |
